[1]
Saini, A.K. et al. 2022. A Retrospective Assessment of The Safety Profile of Pioglitazone in T2dm Patients. Asian Journal of Pharmaceutical Research and Development. 10, 3 (Jun. 2022), 70–77. DOI:https://doi.org/10.22270/ajprd.v10i3.1096.